TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
ALLO

Allogene Therapeutics Inc

Healthcare · Biotechnology

1.70$ +0.0% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement ALLO
Line item 2017 2018 2019 2020 2021 2022 2023 2024 2025
– – – 100.0% 100.0% 100.0% 100.0% 100.0% –
– – – 30.1% 33.9% 6,884.0% 14,946.3% 61,995.5% –
– – – -30.1% 100.0% 100.0% 100.0% 100.0% –
– – – 503.3% 572.0% 105,509.1% 255,698.9% 874,086.4% –
– – – 170.2% 192.5% 32,635.8% 75,445.3% 296,386.4% –
– – – 673.5% 764.6% 138,144.9% 345,086.3% 1,241,913.6% –
– – – -673.5% -664.6% -138,044.9% -344,986.3% -1,241,813.6% –
– – – 23.9% 27.2% 7,042.0% 18,012.6% 822.7% –
– – – -652.6% -667.7% -136,885.6% -344,489.5% -1,168,850.0% –
– – – -43.7% -31.6% -1,159.3% -2,965.3% 2,013.6% –
– – – -608.9% -636.1% -135,726.3% -344,489.5% -1,170,863.6% –
– – – -653.7% -637.4% -132,162.1% -329,543.2% -1,106,031.8% –

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?